Introduction

p16/Ki-67 Dual Staining is an important marker for cervical cancer screening and diagnosis.

The p16/Ki-67 Dual Staining technology is a new detection method joint recommended by CAP and ASCCP, also recommended by Bethesda Version 2015.

Test principle

• p16 causes cell cycle arrest
• Ki-67 marks cell proliferation
• Simultaneous expression suggests a cell cycle disorder, a "carcinoma."

Advantage

• Dual-stainin, specificity is better than HR-HPV
• Positive result of dual staining indicates Cervical cells are cancerous

Higher sensitivity

• Bypassed with higher sensitivity and specificity

Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan District, Shenzhen, P.R. China. is a diagnostics company focused on the development and manufacture of IVD tests at the Point-of-Care with highly innovative proprietary technology.

We focused on the emerging markets of in vitro pathological diagnosis and immunodiagnosis. We developed, manufactured and successfully launched the in vitro immunodiagnosis platform for cancer and the POCT for infectious, genetic and chronic diseases.

<span style="color: rgb(33, 33, 33); text-transform: none; text-indent: 0px; letter-spacing: normal;" initial;"="" initial;="" 0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;="" !important;="" inline="" none;="" 600;="" 14px;="" sans-serif;="" arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",="" hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,="" freesans,="" yahei",="" "microsoft="" helvetica,="" grande",="" "lucida="" ui",="" segoe="">At Kissh we work every day to shape the future of in-vitro diagnostic testing. And our people are our best asset, the reason for our track record and our strength while we are moving forward. We live by our fundamental values and incorporate them in everything that we do. Our best asset is ‘Step Forward Every Second’